[3] DCP has also collaborated in a phosphoproteomics project[4] designed to study the molecular mechanisms in the pathogenesis of transmissible spongiform encephalopathies (TSEs) or prion disease.

Current R&D projects within the company have been focused on developing applications for SILAC quantitative proteomics in predictive toxicology.

DCP initially developed antibodies, mammalian cell fractions for precursor mRNA splicing research and tissue culture media specifically formulated for SILAC quantitative proteomics.

The company has subsequently expanded its products and services portfolio into many other areas of life sciences research to better cover the needs of its customers.

Some of the research services that DCP offers include gene synthesis, DNA cloning, recombinant protein expression and purification, stable cell line development, custom monoclonal and polyclonal antibody development and various proteomics services[5] i.e. both quantitative (e.g. SILAQ, Tandem Mass Tags, iTRAQ, Isotope-coded affinity tag (ICAT), label-free) and qualitative.